Pharmacologic activation of the cholinergic anti-inflammatory pathway reverses obesity-induced insulin resistance

Yael T. Harris¹, Jacqueline Dubuque², LaQueta Hudson³, Sangeeta Chavan³, and Kevin J. Tracey³

1 Elmezzi Graduate School of Molecular Medicine 2 Center for Comparative Physiology, 3 Laboratory of Biomedical Science, Feinstein Institute for Medical Research

Abstract


Introduction: The incidence of metabolic syndrome is significantly increasing in the United States. TNF and other proinflammatory cytokines have been implicated in the pathogenesis of obesity-related insulin resistance. TNF production is controlled by a neural circuit termed the cholinergic anti-inflammatory pathway. Signals transmitted by the vagus nerve suppress TNF release through an alpha7 nicotinic acetylcholine receptor subunit dependent mechanism. We postulated that activating the cholinergic anti-inflammatory pathway by administration of a selective alpha7 nAChR agonist, GTS-21, would reduce TNF-induced insulin resistance and cardiovascular risk in rats fed a high fat diet (HFD). Methods: Rats were fed standard chow, or chow with 10% lard for three weeks. Rats were then treated with GTS-21 (4mg/kg subcut bid) or saline for 1 week. Insulin resistance was measured using an intravenous insulin tolerance test (ITT). Blood samples were taken for measurement of CRP and HDL cholesterol levels

Results: As expected, rats fed a high fat diet for three weeks developed insulin resistance (KITT control 7.42±0.63 %/minute vs KITT HFD 5.09±0.5, n = 8, 9 respectively, p<0.01). Treatment with GTS-21 led to an improvement in insulin sensitivity (KITT saline 4.11±0.49 %/minute, KITT GTS-21 5.15±0.34, n = 6, 5 respectively). Animals treated with GTS-21 also had elevated levels of HDL cholesterol

Conclusions: These results indicate that activation of the cholinergic anti-inflammatory pathway by administration of GTS-21 can improve insulin sensitivity, and may decrease cardiovascular risk.

Introduction

- Prevalence of obesity in the US exceeds 30% of the population
- · Obesity is associated with significant morbidity
- Type 2 diabetes mellitus
- Cardiovascular disease
- Type 2 diabetes = insulin resistance + impaired insulin secretion
- · Obesity leads to diabetes largely by inducing insulin resistance
- Obesity → ↑ pro-inflammatory cytokines → insulin resistance
- Activation of the cholinergic anti-inflammatory pathway suppresses production of proinflammatory cytokines
- GTS-21 is a selective α7 nicotinic acetylcholine receptor agonist




Hypothesis: GTS-21 treatment will reverse insulin resistance in obese rats

Objective

To investigate the effect of pharmacologic activation of the cholinergic anti-inflammatory pathway on insulin resistance and associated cardiovascular risk profile in obese rats

0-4 mg/kg subcut bid Calculate K,







4. Collected blood and tissue samples for analysis of cytokines via ELISA and insulin signaling molecules via immunoblot

Results

Methods






Insulin sensitivity in rats fed a high fat diet and treated with GTS-21 0-4 mg/kg for 0-7days (n=6-9 per group, *p < 0.01)

Metabolic Parameters


	Saline control	GTS-21 treated	P-value
Food Intake (g/rat/day)	27.7 +/- 1.1	26.2 +/- 1.3	0.38
Weight change during tx (g)	18.3 +/- 3.0	13.4 +/- 2.9	0.25
Fasting glucose (mg/dL)	240 +/- 10	254 +/- 10	0.34
Fasting insulin (pg/mL)	630 +/- 77	420 +/- 38	<0.05

GTS-21 enhances insulin signaling



Activated Akt (a key insulin signaling molecule) relative to total Akt in visceral adipose tissue of high fat- fed rats after GTS-21 (4mg/kg) or saline x 1 week (p < 0.05)

GTS-21 treatment decreases inflammation



Cytokine concentrations in visceral adipose tissue of rats fed a high fat diet and treated with GTS-21 (4mg/kg) or saline x 1 week (n= 8-10 per group, * p < 0.05, ** p < 0.01)

Conclusions

 Pharmacologic activation of the cholinergic anti-inflammatory pathway reverses insulin resistance and improves cardiac risk in obese rats

Cardiovascular risk markers

	Saline control	GTS-21 treated	P-value
CRP (mg/dL)	< 0.05	< 0.05	
PAI-1	1.9 +/- 0.3	1.7 +/- 0.3	NS
HDL (mg/dL)	46.5 +/- 1.8	55.5 +/- 2.5	< 0.01
TGF-ß (ng/mL)	82 +/- 3.6	95 +/- 4.7	< 0.05

Future Directions

- · Evaluate effect of cholinergic stimulation on coronary disease in atherosclerosis prone rodents
- · Extend these in vivo findings to human disease in clinical trials evaluating the effect of cholinergic agonists or acetylcholinesterase inhibitors in patients with type 2 diabetes